Home
  • Our Company
    • Biopharmaceutical Acceleration Model®
    • Dynamic Assembly®
    • Kinetic™
    • Syneos One®
    • The Trusted Process®
    • Our Leadership
    • Our Vision, Mission and Values
    • Resource Library
    • Events
    • Awards
    • Site Relationships
    • Our Office Locations
  • Solutions
    • Clinical Development
      • Full Service
        • Bioanalytical Solutions
        • Early Phase
        • Phase II - III
        • Phase IIIb - IV
        • Real World and Late Phase
        • Medical Device and Diagnostics
      • FSP 360
        • Biostatistics and Statistical Programming
        • Clinical Data Management
        • Clinical Development Services Project Management
        • Clinical Monitoring
        • Drug Safety and Pharmacovigilance
        • Investigator Management Solutions
        • Medical Writing and Communications
        • Rater Training
        • Site Start Up
        • Site and Patient Access
        • Trial Master File Operations
    • Commercialization
      • Advertising
      • Behavioral Insights
      • Brand Commercialization
      • Brand Naming and Development
      • Clinical Field Teams
      • Commercial Model of the Future
      • Commercial Recruiting Solutions
      • Communications
      • Deployment Solutions
      • Digital and Social Media
      • Health Economics and Outcomes Research
      • Integrated Commercial Solutions
      • Medical Affairs Transformation
      • Medical Communications
      • Medication Engagement
      • Policy and Advocacy
      • Portfolio Strategy
      • Public Relations
      • REMS and Risk Management (PMO)
      • Reputation and Risk Management
      • Selling Solutions
      • Syndicated Market Research and Insights
      • Training and Learning Solutions
      • Value and Access
    • Consulting
      • Commercial Advisory Group
        • Portfolio Strategy and Transactions
        • Health Economics and Outcomes Research
        • Product and Franchise Strategy
        • Value and Access
        • Customer and Digital Engagement
      • Scientific and Medical Affairs Advisory Group
        • Medical Affairs
        • Quality and Compliance
        • Regulatory
      • Risk and Program Management Advisory Group
        • REMS and Risk Management (PMO)
      • R&D Advisory Group
        • Research and Development
    • Syneos One®
  • Therapeutic Expertise
    • Therapeutic Areas
      • Cardiovascular
      • Central Nervous System
        • CNS Analgesia
        • CNS Clinical Surveillance Team
        • CNS Neurology
        • CNS Psychiatry
      • Endocrine and Metabolic
      • Gastroenterology
      • Immunology and Inflammation
      • Infectious Disease
      • Oncology and Hematology
        • Targeted Therapies
        • Novel and Emerging Therapies
        • Immuno-Oncology
      • Ophthalmology
      • Respiratory
      • Women's Health
    • Cross-Functional Solutions
      • Biosimilars
      • Cell and Gene Therapy
      • Pediatrics
      • Rare Diseases
    • Our Experience Hub
  • Insights Hub
  • Careers
  • 中途採用
  • 新卒採用 (日本)
  • News
    • In The News
    • Press Releases
    • Press Kit
  • Investors
  • Investigators
  • Transparency
  • Suppliers
    • Supplier Code of Conduct
    • Supplier Diversity and Inclusion
    • Supplier Terms and Conditions
  • Contact
  • English
  • Français Canadien
  • 日本語

Search form

Home Insights Hub The 2021 Health Trends Series Fast Launch; Long Tail
Trends

Fast Launch; Long Tail

January 12, 2021
Content 

 

Subscribe to our Newsletter

Fast Launch; Long Tail

2021 Health Trends
Columns 
Content 
Image or Video 

Fast Launch; Long Tail.png

Fast Launch; Long Tail
Content 

 

Regulators around the world are making it possible to get novel and high-potential treatments to patients faster. Through changes in regulations and approaches to review, they’re making it possible for true fast tracks as well as more efficient clinical protocols.

With speed to launch comes a new expectation: more real-world evidence and data. That real-world data has been considered a post-launch cost and commitment in years past, but RWE strategy is moving left on the development timeline. The clear focus in 2021: using RWE to enhance the research and development process, including supporting regulatory filings and augmenting clinical trials. That’s an easier realization of value for companies that have already invested in RWE; others will spend the year building to catch up.

Critical Questions

Where will real-world data and evidence have the most impact on our total costs and market potential?

What transformation is needed in the short-term to fill any gaps?

Sparks for Fast Launch; Long Tail
Columns 
Content 
Image or Video 

15 Percent CAGR.png

15 Percent CAGR

15% CAGR:

Industry is investing in experts, technologies and medical-grade data. By 2024, the RWE solutions market is expected to be valued at $1.64 billion. Driving investment, the analysis revealed, is the need for stronger evidence of treatment impact, clinical value, and cost effectiveness in environments that look more like real life and less like the strongly controlled settings of traditional trials.

— GlobeNewswire, 2020

Content 
Image or Video 

Lag Time.png

Lag Time

Lag Time:

Time to approval is moving faster around the world. In Japan, for example, regulators are combatting drug lag (the extended amount of time it can take for Japanese patients to get access to new treatment vs. the rest of the world) by changing their expectations for Phase 1 / Pharmacokinetics (PK) studies. Those no longer have to be done strictly in region, allowing Japan to more easily be part of global clinical trials.

— Syneos Health, 2020

 

Download a PDF of this content below. 

 

The 2021 Health Trends Series
The Next Normal
Post-Surge Capacity
Download
Download

Fill out the form below to download your requested Insights Hub Article.

*Required fields

By submitting this form, you agree to our Terms & Conditions and Privacy Policy of our website. You can withdraw your consent at any time. If you have any questions, please Contact Us.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Related Content

The 2021 Health Trends Series
December 1, 2020
The Next Normal
January 6, 2021
Post-Surge Capacity
December 31, 2020

Chapters

Chapter:
1
Remote Care
Chapter:
2
The Race to Return Safe
Chapter:
3
Realigning in Real Time
Chapter:
4
Post-Surge Capacity
Chapter:
5
The Next Normal
Chapter:
6
Fast Launch; Long Tail

Pages

  • 1
  • 2
  • next ›
  • last »
Interested in Syneos Health?
Get In Touch
Connect
  • LinkedInLinkedIn
  • TwitterTwitter
  • FacebookFacebook
  • InstagramInstagram

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries.

Contact Us
Our Headquarters
Corporate Headquarters
  • 1030 Sync Street
  • Morrisville, NC 27560
  •  
  • Phone: +1 919 876 9300
  • Fax: +1 919 876 9360
  • Toll-Free: +1 866 462 7373
Menu
  • Solutions
  • Therapeutic Expertise
  • Brand Directory
  • Careers
  • Study Participants
  • Media
  • Business Ethics Helpline
  • Events
  • Transparency
© 2021 Syneos Health. All Rights Reserved.
  • Terms Of Use
  • Privacy Notice
  • Privacy Shield
  • Online Tracking Opt-Out